Pfizer Inc. (NYSE:PFE) Director Scott Gottlieb Purchases 1,000 Shares

Pfizer Inc. (NYSE:PFE) Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Pfizer Trading Down 0.8 %

NYSE PFE opened at $28.29 on Friday. The company has a market cap of $160.31 billion, a P/E ratio of 38.23, a P/E/G ratio of 0.90 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a 50-day moving average of $29.05 and a 200-day moving average of $28.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.94%. Pfizer’s dividend payout ratio is presently 227.03%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently modified their holdings of PFE. Olistico Wealth LLC purchased a new position in Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter worth $29,000. Quarry LP purchased a new position in shares of Pfizer in the 2nd quarter valued at $31,000. Financial Connections Group Inc. acquired a new position in shares of Pfizer during the 2nd quarter valued at $34,000. Finally, ESL Trust Services LLC purchased a new stake in Pfizer during the 1st quarter worth $37,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Citigroup initiated coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.